Nina Shah

MD

Hematologist-oncologist
Multiple myeloma researcher and hematology events planner

About me

Dr. Nina Shah is a specialist in blood diseases who focuses on treating multiple myeloma, a type of cancer affecting certain cells in the bone marrow. Her areas of professional interest include the intersection of immunology and oncology as well as helping patients fight multiple myeloma by boosting their immune systems.

Shah earned a bachelor's degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine. She completed a residency in internal medicine at Columbia University and a fellowship in hematology-oncology at the University of Texas MD Anderson Cancer Center.

Shah belongs to the American Society of Clinical Oncology, American Society of Hematology and American Society for Transplantation and Cellular Therapy. She speaks Bengali and Spanish.

  • Education

    New York University School of Medicine, 2002

  • Residencies

    Columbia University, Internal Medicine, 2005

  • Fellowship

    University of Texas MD Anderson Cancer Center, Hematology-Oncology, 2010

  • Board Certifications

    Hematology, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages

    Bengali

    English

    Spanish

My goal is to see every encounter from the patient’s perspective. By imagining how others feel, I hope to treat the person, not just the patient.

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

Decorative Caduceus

Study of bb21217 in Multiple Myeloma

Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).

Recruiting

Decorative Caduceus

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 2 weeks.

Recruiting

Decorative Caduceus

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

A Phase 1, open-label, single ascending dose (SAD) study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2 open-label efficacy and safety ...

Recruiting

Decorative Caduceus

A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who hav...

Recruiting

Share